# Effect of Prolonged Use of Dronedarone on Recurrence in Patients With Non-paroxysmal Atrial Fibrillation After Radiofrequency Ablation

Study · id `cardio:ct-nct05655468` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05655468](<https://clinicaltrials.gov/study/NCT05655468>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05655468

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 268 participants.

## Technical summary

Registry record NCT05655468. Randomized; quadruple masking; primary purpose treatment. Start 2023-03-29 (actual); primary completion 2025-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 268 participants (planned count; ClinicalTrials.gov record NCT05655468, source copy `cardio:ctgov-nct05655468-2023-04-13`, retrieved 2026-10-26)
- Started: 2023-03-29 (actual) (ClinicalTrials.gov record NCT05655468, source copy `cardio:ctgov-nct05655468-2023-04-13`, retrieved 2026-10-26)
- Primary completion: 2025-04 (anticipated) (ClinicalTrials.gov record NCT05655468, source copy `cardio:ctgov-nct05655468-2023-04-13`, retrieved 2026-10-26)
- Completion: 2025-11 (anticipated) (ClinicalTrials.gov record NCT05655468, source copy `cardio:ctgov-nct05655468-2023-04-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05655468, source copy `cardio:ctgov-nct05655468-2023-04-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05655468-2023-04-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Prolonged Use of Dronedarone on Recurrence in Patients With Non-paroxysmal Atrial Fibrillation After Radiofrequency Ablation
- Acronym: DORIS
- Condition: Atrial Fibrillation
- Intervention (Drug): Dronedarone
- Intervention (Drug): Placebo
- Lead sponsor: Shanghai East Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Shanghai East Hospital (`cardio:org-shanghai-east-hospital`)

## Provenance

Content hash: 6aa2d9eb43b80888fcd7cb56a80da49324e5245c2d0e4be0670ff27c9c979ac5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
